What is the recommended treatment for a 6 mm × 5 mm angiomyolipoma in the left kidney?

Active Surveillance with Periodic Imaging

For a 6 mm × 5 mm renal angiomyolipoma, no treatment is required—active surveillance is the appropriate management strategy. This small, asymptomatic lesion poses minimal risk and does not meet any threshold for intervention 1.

Rationale for Observation

Your angiomyolipoma is well below the size thresholds that trigger treatment considerations:

• Size-based intervention typically begins at ≥3-4 cm, not 6 mm 1, 2, 3
• Lesions <4 cm are generally asymptomatic and remain stable over time 4
• The risk of spontaneous hemorrhage—the main clinical concern with angiomyolipomas—is negligible at this size
• No aneurysms are present (aneurysms ≥5 mm would be a concern, but only in larger tumors) 2

Surveillance Protocol

Follow-up imaging schedule:

• Initial repeat imaging at 6-12 months to establish growth pattern
• If stable: extend to annual imaging for 2-3 years
• If continued stability: consider extending intervals to every 2-3 years
• CT or MRI are both acceptable modalities 2, 5

Monitor for these specific changes:

• Growth rate >0.25 cm/year (would prompt closer follow-up) 2
• Development of intralesional aneurysms
• New symptoms: flank pain, hematuria, or palpable mass
• Increase to ≥4 cm diameter (would trigger treatment discussion)

When Treatment Would Be Indicated

You would only need intervention if:

1. Size reaches ≥4 cm (you're currently at 0.6 cm) 1, 3, 4
2. Rapid growth documented (>0.25 cm/year) 2
3. Symptoms develop (pain, bleeding, hematuria)
4. Hemorrhage occurs (extremely unlikely at this size)
5. Aneurysms ≥5 mm develop within the lesion 2

Special Considerations

If you have tuberous sclerosis complex (TSC): The guidelines 1 discuss mTOR inhibitor therapy (everolimus), but this is reserved for TSC-associated angiomyolipomas ≥3 cm or those with high tumor burden. Your 6 mm lesion would still be observed even in TSC context.

If you are a woman of childbearing age: Some sources suggest closer monitoring due to theoretical increased bleeding risk during pregnancy 2, but at 6 mm, observation remains appropriate with perhaps slightly more frequent imaging.

Common Pitfalls to Avoid

• Do not pursue biopsy—the diagnosis is made radiologically, and biopsy adds unnecessary risk 6
• Do not over-image—excessive radiation from frequent CT scans outweighs any benefit at this size
• Do not confuse this with renal cell carcinoma—classic angiomyolipomas with visible fat on imaging are benign 5, 7

The natural history data shows that small angiomyolipomas like yours have median annual growth of only 0.13 mm, with 43% actually decreasing in size or remaining unchanged over years of follow-up 8. Your lesion requires no treatment, only watchful waiting.